Pharmacokinetics of ABT-335 and Rosuvastatin in Subjects With Normal Renal Function and Renal Impairment

NCT00585143 Phase 1 COMPLETED

Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

Details

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	COMPLETED
Enrolment	37
Start date	2008-01
Completion	2008-10

Conditions

• Dyslipidemia, Renal Insufficiency

Interventions

• ABT-335
• Rosuvastatin

Primary outcomes

• Blood concentrations of the active ingredients and metabolites of ABT-335 and rosuvastatin — Days 1, 8, 9, and 10

Countries

United States